Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui

Agreement represents strong strategic fit that leverages the company’s internal DNA damage response expertise and in-house ADC capabilities

02-Nov-2023 - Merck announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) ...

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success

20-Sep-2023 - Merck announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., ...

Merck and Artios will conduct collaborative research

Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

03-Dec-2020 - Merck and Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs. “Our platform has ...

Merck creates immuno-oncology spin out iOnctura

Initial capital provided by Merck Ventures

21-Jun-2017 - Merck announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). CRT is the commercial arm of ...

Merck Licenses Four Oncology Research and Development Programs from Vertex

Vertex receives upfront payment of $230 million plus royalties on future sales

12-Jan-2017 - Merck announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Inc. for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.“With this strategic deal we ...

Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy

02-Apr-2015 - Merck Serono and Intrexon Corporation announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono’s comprehensive, science-driven strategy to develop ...

Merck Announces Global Strategic Alliance with Pfizer

Alliance accelerates Merck’s entry into the US oncology market

18-Nov-2014 - Merck (MRK GY) announced today that it has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two ...

Lead Discovery Center and Merck KGaA Enter Collaboration for the Discovery of Anti-Cancer Compounds

Research collaboration may realize the potential of kinase inhibitors as a means for cancer treatments in the future

24-Jan-2011 - The Lead Discovery Center GmbH (LDC), a small molecule drug discovery spin-off of Max Planck Innovation GmbH, announced that it has signed a cooperation agreement with Merck KGaA for the discovery of kinase inhibitors as potential cancer treatments. The collaboration is supported by the German ...

Ablynx and Merck Serono enters into second agreement to co-discover and co-develop Nanobodies

12-Oct-2010 - Ablynx and Merck Serono, a division of Merck KGaA, announced that they have expanded their relationship and entered into a second agreement, to co-discover and co-develop Nanobodies against an inflammatory disease target. Ablynx's Nanobodies are a class of antibody-derived therapeutic proteins ...